86649-57-2

Basic information

• Product Name: (PYRIDIN-3-YLOXY)-ACETIC ACID
• Synonyms: (PYRIDIN-3-YLOXY)-ACETIC ACID;BUTTPARK 32\03-53;AKOS BB-3307;3-PAA;3-PYRIDYLOXYACETIC ACID;3-PYRIDINYLOXY ACETIC ACID;2-(pyridin-3-yloxy)acetic acid;2-(3-Pyridyloxy)acetic acid trifluoroacetate
• CAS NO: 86649-57-2
• Molecular Formula: C7H7NO3
• Molecular Weight: 153.14
• Mol File: 86649-57-2.mol
• Article Data: 2

Chemical Properties

• Melting Point: 210-212°C
• Boiling Point: 312.9 °C at 760 mmHg
• Flash Point: 143 °C
• Appearance: /
• Density: 1.3 g/cm³
• Vapor Pressure: 0.000219mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 2.56±0.10(Predicted)
• Water Solubility: Slightly Soluble in water (2.0 g/L)
• CAS DataBase Reference: (PYRIDIN-3-YLOXY)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (PYRIDIN-3-YLOXY)-ACETIC ACID(86649-57-2)
• EPA Substance Registry System: (PYRIDIN-3-YLOXY)-ACETIC ACID(86649-57-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 86649-57-2(Hazardous Substances Data)

Usage

Uses

3-Pyridyloxyacetic acid is used in synthesis of raw material for fine chemicals, organic intermediate, pharmaceutical intermediate.

InChI:InChI=1/C7H7NO3/c9-7(10)5-11-6-2-1-3-8-4-6/h1-4H,5H2,(H,9,10)

Upstream product

• 119967-48-5 methyl 2-(pyridin-3-yloxy)-acetate 
• 109-00-2 3-HYDROXYPYRIDINE 
• 79-11-8 chloroacetic acid 

Downstream Products

• 1698878-14-6 2-hydroxy-2-methyl-N-[2-[2-(3-pyridyloxy)acetyl]-3,4-dihydro-1H-isoquinolin-6-yl]propane-1-sulfonamide 
• 1399857-74-9 6-(4-fluorophenyl)-3-((pyridin-3-yloxy)methyl)[1,2,4]triazolo[4,3-b][1,2,4]triazine 

Relevant articles and documents

ORGANIC COMPOUNDS

The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.